Cambridge, Mass.-based Mersana Therapeutics Inc. laid out in early January development plans that included the discontinuation of XMT-1522, an antibody-drug conjugate (ADC) taking aim at the popular HER2 target, partnered with Takeda Pharmaceutical Co. Ltd.
After having donated the benzimidazole therapy to the World Health Organization (WHO) since 2005 as a way of helping to treat about 2 million patients in more than 30 countries, Novartis AG won approval by the FDA of Egaten (triclabendazole) for fascioliasis, or liver-fluke disease, in patients 6 years of age and older.
Tim Dyer, CEO of Geneva-based Addex Therapeutics SA, told BioWorld that Indivior plc's decision to stop research with addiction candidate ADX-71441 and focus work on other GABAB positive allosteric modulator (PAM) therapies is "not the end of the world. The most important thing for us is that we've got a committed partner. Shifting from a lead asset to a backup – that's the business we're in," he said.
CEO Shawn Singh of Vistagen Therapeutics Inc. called the favorable vote for ketamine derivative esketamine by a joint meeting of FDA advisory panels "the writing of a bright new chapter in the history of neuropsychiatry," telling BioWorld that the "next transformative step" will involve developing more convenient, at-home options. Esketamine is given under medical supervision.
Trouble surfaced early in the joint FDA panel meeting to deliberate the drug-device combo esketamine 28-mg single-use nasal spray from Johnson & Johnson unit Janssen Pharmaceuticals Inc. when an agency official said U.S. gatekeepers didn't necessarily agree about the efficacy offered to support the ketamine-derived therapy for treatment-resistant depression (TRD).
The recent deal between Meiragtx Holdings plc and New Brunswick, N.J.-based Johnson & Johnson (J&J) arm Janssen Pharmaceuticals Inc. drew more eyeballs to companies targeting inherited retinal diseases (IRDs), which can only mean good things for the likes of Nightstar Therapeutics plc.
Although Wall Street hammered shares of Solid Biosciences Inc. (NASDAQ:SLDB) down to $15.15, or 67.8 percent, to close them Thursday at $7.19, company officials told investors of a thesis based on preclinical work that could lead to better results with SGT-001 microdystrophin gene transfer for Duchenne muscular dystrophy (DMD)
Analysts during a conference call with Macrogenics Inc. characterized themselves as "dead wrong" and called the company's phase III victory "especially sweet" with margetuximab (marge) that was "written off by so many" in HER2-positive metastatic breast cancer. The news sent shares (NASDAQ:MGNX) up 130.4 percent, or $14.49, to close Wednesday at $25.60.
Luciano Rossetti, head of global R&D for Merck KGaA's biopharma branch EMD Serono, told BioWorld that "a very elegant molecule, fascinating from a protein-engineering point of view in addition to the biology" lies at the heart of the potential €3.7 billion (US$4.2 billion) deal with Glaxosmithkline plc (GSK).
